A detailed history of Blue Chip Partners, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Blue Chip Partners, Inc. holds 8,227 shares of AMGN stock, worth $2.27 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
8,227
Previous 8,652 4.91%
Holding current value
$2.27 Million
Previous $2.7 Million 1.96%
% of portfolio
0.23%
Previous 0.25%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$309.38 - $337.38 $131,486 - $143,386
-425 Reduced 4.91%
8,227 $2.65 Million
Q2 2024

Jul 29, 2024

SELL
$262.75 - $319.31 $94,852 - $115,270
-361 Reduced 4.01%
8,652 $2.7 Million
Q1 2024

Apr 25, 2024

SELL
$268.87 - $324.56 $300,058 - $362,208
-1,116 Reduced 11.02%
9,013 $2.56 Million
Q4 2023

Feb 05, 2024

SELL
$255.7 - $288.46 $39,377 - $44,422
-154 Reduced 1.5%
10,129 $2.92 Million
Q3 2023

Oct 30, 2023

SELL
$218.65 - $271.46 $203,344 - $252,457
-930 Reduced 8.29%
10,283 $2.76 Million
Q2 2023

Aug 02, 2023

SELL
$214.27 - $253.37 $569,958 - $673,964
-2,660 Reduced 19.17%
11,213 $2.49 Million
Q1 2023

May 01, 2023

SELL
$225.79 - $275.2 $679,627 - $828,352
-3,010 Reduced 17.83%
13,873 $3.35 Million
Q4 2022

Feb 01, 2023

SELL
$229.03 - $291.01 $746,637 - $948,692
-3,260 Reduced 16.18%
16,883 $4.43 Million
Q3 2022

Oct 27, 2022

BUY
$224.46 - $253.15 $15,936 - $17,973
71 Added 0.35%
20,143 $4.54 Million
Q2 2022

Aug 01, 2022

SELL
$230.71 - $256.74 $311,227 - $346,342
-1,349 Reduced 6.3%
20,072 $4.88 Million
Q1 2022

May 04, 2022

SELL
$219.27 - $242.57 $1.09 Million - $1.2 Million
-4,962 Reduced 18.81%
21,421 $5.18 Million
Q4 2021

Feb 08, 2022

SELL
$198.88 - $227.6 $1.22 Million - $1.39 Million
-6,129 Reduced 18.85%
26,383 $5.94 Million
Q3 2021

Nov 02, 2021

SELL
$212.27 - $248.7 $6.09 Million - $7.13 Million
-28,668 Reduced 46.86%
32,512 $6.91 Million
Q2 2021

Aug 03, 2021

BUY
$233.58 - $259.14 $461,320 - $511,801
1,975 Added 3.34%
61,180 $14.9 Million
Q1 2021

May 04, 2021

BUY
$221.91 - $258.6 $303,794 - $354,023
1,369 Added 2.37%
59,205 $14.7 Million
Q4 2020

Feb 05, 2021

BUY
$216.38 - $257.67 $268,960 - $320,283
1,243 Added 2.2%
57,836 $13.3 Million
Q3 2020

Oct 27, 2020

BUY
$234.65 - $260.95 $303,637 - $337,669
1,294 Added 2.34%
56,593 $14.4 Million
Q2 2020

Jul 30, 2020

BUY
$197.81 - $242.74 $336,672 - $413,143
1,702 Added 3.18%
55,299 $13 Million
Q1 2020

May 08, 2020

SELL
$182.24 - $241.7 $560,752 - $743,710
-3,077 Reduced 5.43%
53,597 $10.9 Million
Q4 2019

Feb 11, 2020

BUY
$189.21 - $243.2 $334,334 - $429,734
1,767 Added 3.22%
56,674 $13.7 Million
Q3 2019

Oct 29, 2019

BUY
$174.11 - $208.62 $559,589 - $670,504
3,214 Added 6.22%
54,907 $10.6 Million
Q2 2019

Jul 31, 2019

BUY
$166.7 - $195.41 $434,920 - $509,824
2,609 Added 5.32%
51,693 $9.53 Million
Q1 2019

Apr 23, 2019

BUY
$180.87 - $203.88 $511,862 - $576,980
2,830 Added 6.12%
49,084 $9.33 Million
Q4 2018

Feb 05, 2019

BUY
$178.4 - $208.25 $415,315 - $484,806
2,328 Added 5.3%
46,254 $9 Million
Q3 2018

Oct 26, 2018

BUY
$185.29 - $208.89 $760,615 - $857,493
4,105 Added 10.31%
43,926 $9.11 Million
Q2 2018

Jul 25, 2018

BUY
$166.05 - $186.51 $1.07 Million - $1.2 Million
6,429 Added 19.25%
39,821 $7.35 Million
Q1 2018

Apr 25, 2018

BUY
$169.43 - $198.0 $719,569 - $840,906
4,247 Added 14.57%
33,392 $5.69 Million
Q4 2017

Jan 31, 2018

BUY
$168.79 - $188.59 $659,631 - $737,009
3,908 Added 15.49%
29,145 $5.07 Million
Q3 2017

Nov 07, 2017

BUY
$167.29 - $191.0 $181,676 - $207,426
1,086 Added 4.5%
25,237 $4.71 Million
Q2 2017

Aug 07, 2017

BUY
N/A
24,151
24,151 $4.16 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $147B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Blue Chip Partners, Inc. Portfolio

Follow Blue Chip Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Chip Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blue Chip Partners, Inc. with notifications on news.